

Optimapharm Announces Paul Miller as Chief Commercial Officer

“Joining Optimapharm at this pivotal moment is both an honor and a responsibility. With our expanding presence across Europe and North America, we are uniquely positioned to deliver tailored, high-quality clinical research solutions that meet the evolving needs of our clients and bring medicines faster to patients.” – Paul Miller, Chief Commercial Officer.

Optimapharm, a leading mid-sized, full-service CRO operating across Europe and North America, is pleased to announce the appointment of **Paul Miller** as **Chief Commercial Officer (CCO)**.

With over 15 years of experience in the life sciences industry, Paul has a proven track record of commercial leadership across global markets. His expertise spans successful growth and exits of CROs, profitability enhancement, brand development, and identifying strategic opportunities through innovation. Paul is widely recognized for building high-performing, client-focused teams and delivering tailored solutions that create long-term value in highly regulated and competitive environments.

“As a member of our Senior Leadership Team, Paul will be instrumental in shaping and executing Optimapharm’s commercial vision as we continue to grow and deliver on our promise of excellence, agility, and patient-focused clinical research.” – Ivana Waller, CEO.

As Chief Commercial Officer, Paul will be responsible for leading Optimapharm’s global sales, marketing, and commercial growth strategy. His focus will be on deepening client partnerships, expanding the company’s footprint in key markets, and driving sustained business growth. Paul joins Optimapharm’s Senior Leadership Team, where he will contribute to the broader corporate strategy and execution of the company’s long-term commercial vision.